



# Director/PDMR Shareholding

October 21, 2016 11:43 AM EDT

Released : October 21, 2016 07:43

RNS Number : 1438N

MaxCyte, Inc.

21 October 2016

## **MaxCyte, Inc.**

("MaxCyte" or the "Company")

### **Director/PDMR Sharedealing**

**Maryland, USA - 21 October 2016:** MaxCyte (LSE: MXCT), the revenue-generating developer of next generation cell-based medicines, products and services, announces that it was notified on 20 October 2016 of the following transactions:

- On 19 October 2016, John Johnston, a Non-Executive Director of the Company, purchased 37,500 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") at a price of 96 pence per share; and
- On 20 October 2016, Mr Johnston, purchased 37,500 Ordinary Shares at a price of 98 pence per share, the ("Transactions").

Following the Transactions, Mr Johnston's total beneficial interest in the Company is 75,000 Ordinary Shares, representing approximately 0.17 per cent. of the current issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.**

a)	Name	John Johnston	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial Notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	MaxCyte, Inc.	
b)	Legal Entity Identifier	N/A	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary shares of 0.1 pence each  MXCT / US57777K1060	
b)	Nature of the transaction	Purchase of shares	
c)	Currency	GBP	
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		0.98	37500
		0.96	37500
e)	Aggregated information  - Aggregated volume  - Price  - Aggregated total	75000  0.97  £72,750	

f)	Date of the transaction	19/10/16 20/10/16
g)	Place of the transaction	London Stock Exchange, AIM

**- ENDS -**

**For further information please contact:**

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

***Nominated Adviser and Broker***

+44 (0) 20 7886 2500

**Panmure Gordon**

Freddy Crossley (Corporate Finance)

Fabien Holler

Duncan Monteith

Tom Salvesen (Corporate Broking)

***Financial PR Advisor***

+44 (0)203 709 5700

Consilium Strategic Communications

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

Mary-Jane Elliott

Chris Welsh

Lindsey Neville

**About MaxCyte**

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of \$35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.

MaxCyte's high performance platform allows transfection with any molecule or

multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.

Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.

For more information visit <http://www.maxcyte.com/>

This information is provided by RNS  
The company news service from the London Stock Exchange

END

DSHEAKEFALAKFEF